Circulating memory-effector T-cells useful marker for predicting alefacept responders

September 1, 2001

In patients with chronic plaque psoriasis treatedwith the human LFA-3/IgG1 fusion protein alefacept (Amevive), early reductionin circulating memory-effector CD45RO+ T-cells may be used to predict ultimateclinical improvement,